Protagonist Therapeutics Inc
PTGX
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.92B
Close$
$-4.08
102.6% downside
Current Fair Value
102.6% downsideOvervalued by 102.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.92 Billion |
|---|---|
| Enterprise Value | $9.52 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.05 |
| Beta | 1.79 |
| Outstanding Shares | 65,935,769 |
Return
| Return on Equity | 9.85% |
|---|---|
| Return on Assets | 9.36% |
| Return on Invested Capital | 8.36% |
Valuation & Multiples
| P/E Ratio | 126.69 |
|---|---|
| PEG | -22.29 |
| Price to Sales | 52.45 |
| Price to Book Ratio | 13.11 |
| Enterprise Value to Revenue | 41.18 |
| Enterprise Value to EBIT | 134.28 |
| Enterprise Value to Net Income | 114 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$2.27
Average shareholder expectationRevenue Estimate
$212.03 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$2.19
Average shareholder expectationRevenue Estimate
$219.85 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5935▲ 36.00% |
|---|---|
| Total Calls | 396,100▲ 36.63% |
| Total Puts | 235,100▲ 247.27% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 117.16%▼ 6.71% |
|---|---|
| Total Invested | $9.35B▲ 12.66% |
| Investors Holding | 351▲ 19.00% |
ESG Score
No data